Citations (49)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Muhammad Umair Mushtaq, Alexandra M. Harrington, Sibgha Gull Chaudhary, Laura C. Michaelis, Karen-Sue B. Carlson, Sameem Abedin, Lyndsey Runass, Natalie S. Callander, Michael J. Fallon, Mark Juckett, Aric C. Hall, Peiman Hematti, Ryan J. Mattison, Ehab L. Atallah & Guru Subramanian Guru Murthy. (2021) Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia. Leukemia & Lymphoma 62:1, pages 158-166.
Read now
Read now
Qianying Pan & Juan Li. (2021) Efficacy and safety of cladribine addition to induction treatment of newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis. Hematology 26:1, pages 577-587.
Read now
Read now
Anqi Zhou, Qi Han, Huihui Song, Jie Zi, Jinlong Ma & Zheng Ge. (2019) Efficacy and toxicity of cladribine for the treatment of refractory acute myeloid leukemia: a meta-analysis. Drug Design, Development and Therapy 13, pages 1867-1878.
Read now
Read now
Chantal Fridle, Michael Medinger, Matthias C. Wilk, Katja Seipel, Jakob Passweg, Markus G. Manz & Thomas Pabst. (2017) Cladribine, cytarabine and idarubicin (CLA-Ida) salvage chemotherapy in relapsed acute myeloid leukemia (AML). Leukemia & Lymphoma 58:5, pages 1068-1075.
Read now
Read now
Tadeusz Robak. (2003) Purine Nucleoside Analogues in the Treatment of Myleoid Leukemias. Leukemia & Lymphoma 44:3, pages 391-409.
Read now
Read now
Tadeusz Robak & Agata Wrzesień-Kuś. (2002) The Search for Optimal Treatment in Relapsed and Refractory Acute Myeloid Leukemia. Leukemia & Lymphoma 43:2, pages 281-291.
Read now
Read now
Articles from other publishers (43)
Chengtao Zhang, Da Gao, Xiaohong Wang, Xiuli Sun, Yan Yan, Yan Yang, Jingjing Zhang & Jinsong Yan. (2023) Effectiveness of chemotherapy using bortezomib combined with homoharringtonine and cytarabine in refractory or relapsed acute myeloid leukemia: a phase II, multicenter, prospective clinical trial. Frontiers in Oncology 13.
Crossref
Crossref
Han Yao, Cheng Zhang, Xu Tan, Jieping Li, Xiaolin Yin, Xiaojuan Deng, Ting Chen, Jun Rao, Lei Gao, Peiyan Kong & Xi Zhang. (2023)
Efficacy and toxicity of
CLAG
combined with pegylated liposomal doxorubicin in the treatment of refractory or relapsed acute myeloid leukemia
. Cancer Medicine 12:11, pages 12377-12387.
Crossref
Crossref
Shai Shimony, Maximilian Stahl & Richard M. Stone. (2023) Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management. American Journal of Hematology 98:3, pages 502-526.
Crossref
Crossref
Gregory W. Roloff, Olatoyosi Odenike, Ashish Bajel, Andrew H. Wei, Nicole Foley & Geoffrey L. Uy. (2022) Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022. American Society of Clinical Oncology Educational Book:42, pages 568-583.
Crossref
Crossref
Silvia Park, Daehun Kwag, Tong Yoon Kim, Jong Hyuk Lee, Joon yeop Lee, Gi June Min, Sung Soo Park, Seung-Ah Yahng, Young-Woo Jeon, Seung-Hwan Shin, Jae-Ho Yoon, Sung-Eun Lee, Byung Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Jong Wook Lee & Hee-Je Kim. (2022)
A retrospective comparison of salvage intensive chemotherapy
versus
venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)
. Therapeutic Advances in Hematology 13, pages 204062072210816.
Crossref
Crossref
Karin Mayer, Corinna Hahn‐Ast, Katjana Schwab, Ingo G. H. Schmidt‐Wolf, Peter Brossart, Axel Glasmacher & Marie von Lilienfeld‐Toal. (2020) Long‐term follow‐up of Cladribine, high‐dose Cytarabine, and Idarubicin as salvage treatment for relapsed acute myeloid leukemia and literature review. European Journal of Haematology 104:6, pages 538-545.
Crossref
Crossref
Na Zhang, Jing-Bo Shao, Hong Li, Jing-Wei Yang, Kai Chen, Jia-Shi Zhu & Hui Jiang. (2019) Re-induction with modified CLAG regimen in relapsed or refractory acute myeloid leukemia in children bridging to allogeneic hematopoietic stem cell transplantation. World Journal of Pediatrics 16:2, pages 152-158.
Crossref
Crossref
I. I. Kalinina, N. V. Zacharov, D. A. Venev, T. Yu. Salimova, U. N. Petrova, O. V. Goronkova, D. D. Baydildina, E. V. Suntcova, M. N. Sadovskay, D. A. Evseev, V. E. Matveev, K. S. Antonova, I. G. Khamin, M. E. Dubrovina, Yu. V. Olshanskaya, E. A. Zerkalenkova, A. I. Mandgieva, D. N. Balashov, L. N. Shelikhova, M. A. Maschan, G. A. Novichkova & A. A. Maschan. (2020) The results of treatment in children with AML and initial hyperleucocytosis according to the AML-MM-2006 Protocol. Pediatric Hematology/Oncology and Immunopathology 19:1, pages 9-17.
Crossref
Crossref
N. V. Zacharov, I. I. Kalinina, D. A. Venev, T. Y. Salimova, D. A. Evseev, O. V. Goronkova & A. A. Maschan. (2020) Hyperleucocytosis in children with acute mieloid leukemia. Pediatric Hematology/Oncology and Immunopathology 19:1, pages 116-121.
Crossref
Crossref
Peipei Ye, Renzhi Pei, Jie Jin, Jie Sun, Kongfei Li, Junjie Cao, Dandan Zhou & Ying Lu. (2019) Modified cladribine, cytarabine, and G-CSF as a salvage regimen in patients with relapsed/refractory acute myeloid leukemia: a bridge to myeloablative allogeneic hematopoietic stem cell transplantation. Annals of Hematology 98:9, pages 2073-2080.
Crossref
Crossref
Ayman Qasrawi, Waled Bahaj, Lien Qasrawi, Omar Abughanimeh, John Foxworth & Rakesh Gaur. (2018) Cladribine in the remission induction of adult acute myeloid leukemia: where do we stand?. Annals of Hematology 98:3, pages 561-579.
Crossref
Crossref
Juan Eduardo Megías-Vericat, David Martínez-Cuadrón, Miguel Ángel Sanz & Pau Montesinos. (2018) Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review. Annals of Hematology 97:7, pages 1115-1153.
Crossref
Crossref
Daniel J. DeAngelo, Andrew M. Brunner, Lillian Werner, David Avigan, Amir T. Fathi, Adam S. Sperling, Abigail Washington, Dina Stroopinsky, Jacalyn Rosenblatt, Malgorzata McMasters, Katarina Luptakova, Martha Wadleigh, David P. Steensma, Gabriela S. Hobbs, Eyal C. Attar, Philip C. Amrein, Benjamin L. Ebert, Richard M. Stone & Karen K. Ballen. (2017) A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. American Journal of Hematology 93:2, pages 254-261.
Crossref
Crossref
J. Zhang, Y. Sun, X. Zhang, B. Long, Y. Lu & X. Li. (2018) Treatment of High-Risk Acute Myeloid Leukemia With Cladribine, Cytarabine, Mitoxantrone, and Granulocyte Colony-Stimulating Factor Then Subsequent Bridging to Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation: A Case Series. Transplantation Proceedings 50:1, pages 246-249.
Crossref
Crossref
Abu-Sayeef Mirza, Jeffrey E. Lancet, Kendra Sweet, Eric Padron, Javier Pinilla-Ibarz, Lisa Nardelli, Christopher Cubitt, Alan F. List & Rami S. Komrokji. (2017) A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 17:12, pages 902-907.
Crossref
Crossref
Karen Seiter, Nasir Ahmed, Azfar Shaikh, Paul Baskind & Delong Liu. (2016) CLAG-based induction therapy in previously untreated high risk acute myeloid leukemia patients. Leukemia Research 46, pages 74-78.
Crossref
Crossref
Katherine Linder, Deepthi Gandhiraj, Madhura Hanmantgad, Karen Seiter & Delong Liu. (2016) Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG. Experimental Hematology & Oncology 5:1.
Crossref
Crossref
Jeffrey C. Bryan & Elias J. Jabbour. (2015) Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments. Drugs & Aging 32:8, pages 623-637.
Crossref
Crossref
Kamal K.S. Abbi, Witold Rybka, W. Christopher Ehmann & David F. Claxton. (2015) Phase I/II Study of Clofarabine, Etoposide, and Mitoxantrone in Patients With Refractory or Relapsed Acute Leukemia. Clinical Lymphoma Myeloma and Leukemia 15:1, pages 41-46.
Crossref
Crossref
Craig W. Freyer, Neha Gupta, Meir Wetzler & Eunice S. Wang. (2015) Revisiting the role of cladribine in acute myeloid leukemia: An improvement on past accomplishments or more old news?. American Journal of Hematology 90:1, pages 62-72.
Crossref
Crossref
Amir T. Fathi & Yi-Bin Chen. (2014) Treatment of Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. Current Hematologic Malignancy Reports 9:2, pages 186-192.
Crossref
Crossref
Jennifer Davila, Emily Slotkin & Thomas Renaud. (2013) Relapsed and Refractory Pediatric Acute Myeloid Leukemia: Current and Emerging Treatments. Pediatric Drugs 16:2, pages 151-168.
Crossref
Crossref
Pawel Robak & Tadeusz Robak. (2013) Older and new purine nucleoside analogs for patients with acute leukemias. Cancer Treatment Reviews 39:8, pages 851-861.
Crossref
Crossref
Nicholas D. Reese & Gary J. Schiller. (2013) High-Dose Cytarabine (HD araC) in the Treatment of Leukemias: a Review. Current Hematologic Malignancy Reports 8:2, pages 141-148.
Crossref
Crossref
Ursula Creutzig. 2013. Childhood Leukemias. Childhood Leukemias
421
428
.
Myke R. Green & Joseph E. Woolery. (2011) Optimising absorption of posaconazole. Mycoses 54:6, pages e775-e779.
Crossref
Crossref
Andrew Wei & Tse-Chieh Teh. (2011) Salvaging AML with CLAG: Novel option, or more of the same?. Leukemia Research 35:3, pages 297-298.
Crossref
Crossref
Mike G. Martin, John S. Welch, Kristan Augustin, Lindsay Hladnik, John F. DiPersio & Camille N. Abboud. (2009) Cladribine in the Treatment of Acute Myeloid Leukemia: A Single-Institution Experience. Clinical Lymphoma and Myeloma 9:4, pages 298-301.
Crossref
Crossref
J E Rubnitz, K R Crews, S Pounds, S Yang, D Campana, V V Gandhi, S C Raimondi, J R Downing, B I Razzouk, C-H Pui & R C Ribeiro. (2009) Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial. Leukemia 23:8, pages 1410-1416.
Crossref
Crossref
Jennifer J. Clark, Jason N. Berman & A. Thomas Look. 2009. Oncology of Infancy and Childhood. Oncology of Infancy and Childhood
331
402
.
Alison R. Walker, Rami S. Komrokji, Jainulabdeen Ifthikharuddin, Patti Messina, Deborah Mulford, Michael Becker, Jonathan Friedberg, Jamie Oliva, Gordon Phillips, Jane L. Liesveld & Camille Abboud. (2008) Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. Leukemia Research 32:12, pages 1830-1836.
Crossref
Crossref
Jerzy Hołowiecki, Sebastian Grosicki, Sławomira Kyrcz-Krzemien, Aleksander B. Skotnicki, Beata Piatkowska-Jakubas, Krzysztof Warzocha, Ilona Seferynska & Barbara Zdziarska. (2007) Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome—Polish Adult Leukemia Group (PALG) pilot study. Annals of Hematology 87:5, pages 361-367.
Crossref
Crossref
Agnieszka Wierzbowska, Tadeusz Robak, Agnieszka Pluta, Ewa Wawrzyniak, Barbara Cebula, Jerzy Hołowiecki, Sławomira Kyrcz-Krzemień, Sebastian Grosicki, Sebastian Giebel, Aleksander B. Skotnicki, Beata Piątkowska-Jakubas, Kazimierz Kuliczkowski, Marek Kiełbiński, Krystyna Zawilska, Janusz Kłoczko & Agata Wrzesień-Kuś. (2007) Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukem. European Journal of Haematology 80:2, pages 115-126.
Crossref
Crossref
Syed Abutalib & Martin S. Tallman. 2008. Acute Leukemias. Acute Leukemias
57
76
.
Scott C. Howard, Raul C. Ribeiro & Ching-Hon Pui. 2010. Childhood Leukemias. Childhood Leukemias
709
749
.
Ursula Creutzig. 2010. Childhood Leukemias. Childhood Leukemias
540
547
.
Tieran Han, Marilyn Fernandez, Ting-Chao Chou & Ram P. Agarwal. (2005) Quantitation of synergism of arabinosylcytosine and cladribine against the growth of arabinosylcytosine-resistant human lymphoid cells. Journal of Cancer Research and Clinical Oncology 131:9, pages 609-616.
Crossref
Crossref
A. Wrzesień-Kuś, T. Robak, A. Wierzbowska, E. Lech-Marańda, A. Pluta, E. Wawrzyniak, A. Krawczyńska, K. Kuliczkowski, G. Mazur, M. Kiebiński, A. Dmoszyńska, M. Wach, A. Hellmann, W. Baran, J. Hołowiecki, S. Kyrcz-Krzemień & S. Grosicki. (2005) A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group. Annals of Hematology 84:9, pages 557-564.
Crossref
Crossref
J Holowiecki, S Grosicki, T Robak, S Kyrcz-Krzemien, S Giebel, A Hellmann, A Skotnicki, W W Jedrzejczak, L Konopka, K Kuliczkowski, B Zdziarska, A Dmoszynska, B Marianska, A Pluta, K Zawilska, M Komarnicki, J Kloczko, K Sulek, O Haus, B Stella-Holowiecka, W Baran, B Jakubas, M Paluszewska, A Wierzbowska, M Kielbinski & K Jagoda. (2004) Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia 18:5, pages 989-997.
Crossref
Crossref
Jeffrey E Rubnitz, Bassem I Razzouk, Deo Kumar Srivastava, Ching-Hon Pui, Raul C Ribeiro & Victor M Santana. (2004) Phase II trial of cladribine and cytarabine in relapsed or refractory myeloid malignancies. Leukemia Research 28:4, pages 349-352.
Crossref
Crossref
A. Wrzesień-Kuś, T. Robak, E. Lech-Marańda, A. Wierzbowska, A. Dmoszyńska, M. Kowal, J. Hołowiecki, S. Kyrcz-Krzemień, S. Grosicki, S. Maj, A. Hellmann, A. Skotnicki, W. Je˛drzejczak & K. Kuliczkowski. (2003) A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG). European Journal of Haematology 71:3, pages 155-162.
Crossref
Crossref
Anna Szmigielska-Kaplon, Ewa Ciesielska, Leszek Szmigiero & Tadeusz Robak. (2002)
Anthracyclines potentiate activity against murine leukemias L1210 and P388
in vivo
and
in vitro
. European Journal of Haematology 68:6, pages 370-375.
Crossref
Crossref
. (2001) Current Awareness. Hematological Oncology 19:1, pages 35-42.
Crossref
Crossref